omniture

RuiYi and iHuman Institute Form Collaboration to Identify Novel Antibodies Targeting GPCRs

RuiYi Inc.
2014-06-11 20:00 2676
  • New antibodies generated with RuiYi's iCAPS technology to explore GPCR structure and function

LA JOLLA, Calif. and SHANGHAI, June 11, 2014 /PRNewswire/ -- RuiYi, a global therapeutic innovation leader, and iHuman Institute at ShanghaiTech University announced today a new research collaboration applying RuiYi's iCAPS (Intermembranous Conformation Antigen Presenting System) technology to create novel monoclonal antibodies with specific binding to G protein coupled receptors (GPCRs) to investigate the biological function and structure of GPCRs.

"As mediators of cellular communication, GPCRs and their related intracellular proteins play a central role in human biology and are important targets in mediating physiological processes to treat disease," said Ray Stevens, Ph.D., founding director of iHuman Institute and scientific founder of RuiYi. "The evolution and power of RuiYi's iCAPS technology enables the generation of antibodies to GPCRs with great selectivity, which can be used not only for antibody therapeutic development but also for probing the structure, function, chemical probe discovery, and signaling pathways of GPCRs."

Dr. Stevens founded the iHuman Institute in 2012 to focus on human cell signaling research. In 2007, the Stevens Laboratory and his colleagues opened the door to multiple high-resolution structures of human GPCRs with follow on functional studies. His efforts have produced a significant amount of the current GPCR structure-function data available to the scientific community.

"At the iHuman Institute, the researchers integrate multiple tools for scientific discovery for advancing human cell signaling research and drug discovery," said Dr. Jie Yin, vice president and provost of ShanghaiTech University. "I look forward to seeing the collaboration help to decipher the mysteries of GPCR signaling."

"Bringing RuiYi's iCAPS technology to iHuman Institute will synergize research efforts in elucidating GPCR structure-function and how structure affects the physiological function," said Paul Grayson, president and CEO of RuiYi. "The knowledge gained from this collaboration will not only advance the scientific understanding of human cell signaling but also help us better identify selective antibody inhibitors or activators for more effective therapeutics."

Source: RuiYi Inc.
collection